Search results
Larimar (LRMR) Up on Lifting of Partial Clinical Hold on FA Study
Zacks· 3 days agoFree Report) announced that the FDA has removed the partial clinical hold on its nomlabofusp (CTI-1601) clinical program following a review of the phase II dose exploration study data. Shares ...
Biogen to acquire privately held Human Immunology Biosciences for $1.15 billion upfront
Market Watch· 3 days agoThe drug has received Breakthrough Therapy Designation and Orphan Drug Designation from the U.S....
SuVax™ and MarVax™ Thermostable Vaccine Platform to be Presented at the Vaccine Technology IX...
FOX 23 News Albany· 4 days agoSoligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an ...
Calliditas Q1 report, January - March 2024
FOX 59 Indianapolis· 2 days agoNet sales amounted to SEK 295.5 million, of which TARPEYO® net sales amounted to SEK 278.3 million, for the three months ended March 31, 2024. For the...
Vedanta Biosciences doses first subject in Phase III C difficile prevention trial
Clinical Trials Arena via Yahoo Finance· 3 days agoIt consists of a specifically designed bacterial consortium and has been recognised by the US Food...
Larimar (LRMR) Up on Lifting of Partial Clinical Hold on FA Study
Zacks via Yahoo Finance· 3 days agoInterim data from the OLE study is expected to be announced in the fourth quarter of 2024....
Mabwell Announces 9MW2821 Clinical Data and Latest Progress to be presented at 2024 ASCO Annual...
FOX 59 Indianapolis· 1 day agoMabwell (688062.SH), an innovation-driven biopharmaceutical company, announced the data and latest...
Biogen to acquire HI-Bio for up to $1.8 billion By Investing.com
Investing.com· 3 days agoHI-Bio's lead asset, felzartamab, is an anti-CD38 monoclonal antibody with Breakthrough Therapy...
FDA lifts hold on Larimar's Friedreich's Ataxia drug study By Investing.com
Investing.com· 5 days agoLarimar Therapeutics, Inc. (NASDAQ:LRMR), a biotechnology firm engaged in developing treatments for...
Biogen is buying up an immune drug developer for $1.8 billion
Quartz· 3 days agoBiotechnology giant Biogen said on Wednesday that it is acquiring immune drug developer Human...
